Alpidem
A non-benzodiazepine anxiolytic that binds to peripheral benzodiazepine receptors and was developed to treat anxiety without the dependence risk of classic benzodiazepines. It was withdrawn from markets due to rare but serious liver toxicity despite initially showing promise for anxiety treatment.
Peso Molecular
404,3000 g/mol
LogP
4,80
TPSA
37,60 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12
InChI
InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3
Molecular Formula
C21H23Cl2N3O
HBD / HBA
- / 2
Ligações Rotacionáveis
7
Átomos Pesados
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A non-benzodiazepine anxiolytic that binds to peripheral benzodiazepine receptors and was developed to treat anxiety without the dependence risk of classic benzodiazepines. It was withdrawn from markets due to rare but serious liver toxicity despite initially showing promise for anxiety treatment.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Alpidem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL54349. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54897. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alpidem"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alpidem/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alpidem/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alpidem/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alpidem"></drugfyi-drug>